{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T08:38:48Z","timestamp":1771922328642,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2023GXNSFAA026099"],"award-info":[{"award-number":["2023GXNSFAA026099"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Health Alliance Charitable Foundation","award":["TB209001"],"award-info":[{"award-number":["TB209001"]}]},{"name":"Scientific Research Project of the Second Affiliated Hospital of Guangxi Medical University","award":["EFYKY2020011"],"award-info":[{"award-number":["EFYKY2020011"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>CD79B is a key component of the B-cell receptor complex, but its relevance in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We screened immune-related genes in public MDS microarray datasets, prioritized CD79B, and validated its expression in an independent MDS cohort, an AML cohort, and peripheral blood samples from patients with MDS or AML transformed from MDS. Functional effects of CD79B overexpression were examined in HL-60 cells, and gene set enrichment and immune-infiltration analyses were used to explore CD79B-associated pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CD79B expression was consistently reduced in MDS and AML compared with normal controls in public datasets and clinical samples. In HL-60 cells, enforced CD79B expression modestly altered cell-cycle distribution and increased apoptosis. Transcriptomic analyses linked higher CD79B expression to immune response and T-cell activation pathways and to global patterns of immune-cell infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These exploratory data suggest that CD79B downregulation is a recurrent feature of MDS and AML and that CD79B may influence leukemic cell behavior and immune microenvironmental signals. The findings generate hypotheses for future mechanistic studies and evaluation of CD79B as a potential biomarker in myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1650035","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:21:44Z","timestamp":1768540904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CD79B in myelodysplastic syndromes and acute myeloid leukemia: an integrative computational and in vitro study"],"prefix":"10.3389","volume":"12","author":[{"given":"Xiangjing","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Hematology, The Second People\u2019s Hospital of Nanning City","place":["Nanning, Guangxi Zhuang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongfu","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, The Second People\u2019s Hospital of Nanning City","place":["Nanning, Guangxi Zhuang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second People\u2019s Hospital of Nanning City","place":["Nanning, Guangxi Zhuang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second People\u2019s Hospital of Nanning City","place":["Nanning, Guangxi Zhuang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Scientific Research Project, Wuhan Kindstar Medical Laboratory Co., Ltd.","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second People\u2019s Hospital of Nanning City","place":["Nanning, Guangxi Zhuang Autonomous Region, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Second Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.bulcan.2023.06.008","article-title":"Facteurs pronostiques des syndromes my\u00e9lodysplasiques","volume":"110","author":"Gyan","year":"2023","journal-title":"Bull Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000535628","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: current guidelines, therapies, and future considerations","volume":"147","author":"DiGennaro","year":"2024","journal-title":"Acta Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-023-01523-4","article-title":"Vaccines: a promising therapy for myelodysplastic syndrome","volume":"17","author":"Gera","year":"2024","journal-title":"J Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1182\/blood.2023020078","article-title":"Diagnosis and classification of myelodysplastic syndromes","volume":"142","author":"Hasserjian","year":"2023","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.3324\/haematol.2022.281444","article-title":"CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine","volume":"108","author":"Karantanos","year":"2022","journal-title":"Haematologica"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1055\/a-2088-3718","article-title":"Efficacy and safety of valproic acid in myelodysplastic syndrome and acute myeloid leukemia; a narrative review","volume":"73","author":"Omidkhoda","year":"2023","journal-title":"Drug Res"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e66093","DOI":"10.3791\/66093","article-title":"Identifying bone marrow microenvironmental populations in myelodysplastic syndrome and acute myeloid leukemia","volume":"201","author":"Kaszuba","year":"2023","journal-title":"J Vis Exp"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2022018718","article-title":"Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML","volume":"142","author":"Bennett","year":"2023","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12885-023-11259-6","article-title":"Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"23","author":"Du","year":"2023","journal-title":"BMC Cancer"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.3324\/haematol.2022.282570","article-title":"Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial","volume":"108","author":"Schroeder","year":"2023","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.3390\/cancers13195026","article-title":"Immune therapies for myelodysplastic syndromes and acute myeloid leukemia","volume":"13","author":"Kapoor","year":"2021","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.3390\/ijms24065515","article-title":"A liquid\u2013liquid phase separation-related index associate with biochemical recurrence and tumor immune environment of prostate cancer patients","volume":"24","author":"You","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"20406207241257904","DOI":"10.1177\/20406207241257904","article-title":"Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine","volume":"15","author":"Zeidan","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.leukres.2017.09.003","article-title":"Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients","volume":"62","author":"Ou","year":"2017","journal-title":"Leuk Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.3892\/ol.2018.9237","article-title":"Integrated bioinformatic analysis of microarray data reveals shared gene signature between MDS and AML","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"872999","DOI":"10.3389\/fonc.2022.872999","article-title":"The differential expression of CD47 may be related to the pathogenesis from myelodysplastic syndromes to acute myeloid leukemia","volume":"12","author":"Yan","year":"2022","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12967-020-02638-9","article-title":"Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients","volume":"19","author":"Liu","year":"2021","journal-title":"J Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/leu.2011.172","article-title":"Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML","volume":"25","author":"de Jonge","year":"2011","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2014-04-569780","article-title":"The TAK1-NF-\u03baB axis as therapeutic target for AML","volume":"124","author":"Bosman","year":"2014","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1038\/ncomms6901","article-title":"Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes","volume":"6","author":"Gerstung","year":"2015","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/leu.2010.31","article-title":"Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells","volume":"24","author":"Pellagatti","year":"2010","journal-title":"Leukemia"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"10658","DOI":"10.3390\/ijms221910658","article-title":"BCL-2 inhibitor ABT-737 effectively targets leukemia-initiating cells with differential regulation of relevant genes leading to extended survival in a NRAS\/BCL-2 mouse model of high risk-myelodysplastic syndrome","volume":"22","author":"Gorombei","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e19342","DOI":"10.1016\/j.heliyon.2023.e19342","article-title":"Prognostic and immunological characterization of diffuse large B-cell lymphoma evaluated by co-stimulatory molecular-related features","volume":"9","author":"Sheng","year":"2023","journal-title":"Heliyon"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e17598","DOI":"10.1016\/j.heliyon.2023.e17598","article-title":"A pan-cancer analysis of SLC1A5 in human cancers","volume":"9","author":"Ni","year":"2023","journal-title":"Heliyon"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1007\/s10495-024-01996-9","article-title":"SNCA is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients","volume":"29","author":"Chen","year":"2024","journal-title":"Apoptosis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12920-024-01853-3","article-title":"SLC27A2 is a potential immune biomarker for hematological tumors and significantly regulates the cell cycle progression of diffuse large B-cell lymphoma","volume":"17","author":"Wang","year":"2024","journal-title":"BMC Med Genet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e70037","DOI":"10.1111\/jcmm.70037","article-title":"A comprehensive prognostic and immune infiltration analysis of UBA1 in pan-cancer: a computational analysis and in vitro experiments","volume":"28","author":"Chen","year":"2024","journal-title":"J Cell Mol Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"18693","DOI":"10.1038\/s41598-019-54917-1","article-title":"Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e24857","DOI":"10.1016\/j.heliyon.2024.e24857","article-title":"GPX4 is a potential diagnostic and therapeutic biomarker associated with diffuse large B lymphoma cell proliferation and B cell immune infiltration","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1007\/s10495-024-01959-0","article-title":"DLD is a potential therapeutic target for COVID-19 infection in diffuse large B-cell lymphoma patients","volume":"29","author":"Chen","year":"2024","journal-title":"Apoptosis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.3390\/ijms21197140","article-title":"Expression, regulation and function of microRNA as important players in the transition of MDS to secondary AML and their cross talk to RNA-binding proteins","volume":"21","author":"Bauer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/10600280211036154","article-title":"Targeting the myeloid lineages and the immune microenvironment in myelodysplastic syndromes: novel and evolving therapeutic strategies","volume":"56","author":"Chung","year":"2022","journal-title":"Ann Pharmacother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s43018-022-00480-0","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2022","journal-title":"Nat Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.3390\/cancers12102913","article-title":"Oncogenic mutations of MYD88 and CD79B in diffuse large B-cell lymphoma and implications for clinical practice","volume":"12","author":"Visco","year":"2020","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1286700","DOI":"10.3389\/fimmu.2023.1286700","article-title":"RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma","volume":"14","author":"Emde-Rajaratnam","year":"2023","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"20406207211072839","DOI":"10.1177\/20406207211072839","article-title":"MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy","volume":"13","author":"Chen","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"eadj4857","DOI":"10.1126\/science.adj4857","article-title":"A blueprint for tumor-infiltrating B cells across human cancers","volume":"384","author":"Ma","year":"2024","journal-title":"Science"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ccell.2021.09.007","article-title":"B cells and cancer","volume":"39","author":"Engelhard","year":"2021","journal-title":"Cancer Cell"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.3390\/cancers14225656","article-title":"Bone marrow immune microenvironment in myelodysplastic syndromes","volume":"14","author":"Kouroukli","year":"2022","journal-title":"Cancer"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.5772\/64618","article-title":"Immune dysregulation in myelodysplastic syndromes: Pathogenetic-pathophysiologic aspects and clinical consequences","volume-title":"Myelodysplastic syndromes","author":"Symeonidis","year":"2016"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1650035\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:34:03Z","timestamp":1771918443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1650035\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":43,"alternative-id":["10.3389\/fmed.2025.1650035"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1650035","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1650035"}}